Really interesting topic and it’s not infrequent I have patients asking me about adding hyperbaric oxygen to standard of care treatments. Given a low risk intervention I think it’s worth exploring bringing clinical trials to community cancer centers that already have access to HBOT. At the very least it’s worth more discussion among oncology researchers. I’ll look for anything out there at ASCO this weekend. The only limitation I see in that case is that delayed responses are not uncommon with immunotherapy sometimes 4 or 5 months after starting treatment we start to see responses in immunogenic cancers so that may have been an explanation of response in that case.
Thank you for sharing. This is enlightening, as I rarely hear oncologists discussing it at the hem/onc conferences I cover for work. I like that HBOT appears to be a low-risk intervention with the potential to significantly transform prognosis.
Is “waiting it out” for a delayed immunotherapy response a common approach, or does it vary considerably from case to case, as I would assume? If you have any suggested readings, I'd love to look more into it.
Really interesting topic and it’s not infrequent I have patients asking me about adding hyperbaric oxygen to standard of care treatments. Given a low risk intervention I think it’s worth exploring bringing clinical trials to community cancer centers that already have access to HBOT. At the very least it’s worth more discussion among oncology researchers. I’ll look for anything out there at ASCO this weekend. The only limitation I see in that case is that delayed responses are not uncommon with immunotherapy sometimes 4 or 5 months after starting treatment we start to see responses in immunogenic cancers so that may have been an explanation of response in that case.
Thank you for sharing. This is enlightening, as I rarely hear oncologists discussing it at the hem/onc conferences I cover for work. I like that HBOT appears to be a low-risk intervention with the potential to significantly transform prognosis.
Is “waiting it out” for a delayed immunotherapy response a common approach, or does it vary considerably from case to case, as I would assume? If you have any suggested readings, I'd love to look more into it.